These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 20220778)

  • 21. [Genetic abnormalities in multiple myeloma: role in oncogenesis and impact on survival].
    Decaux O; Lodé L; Minvielle S; Avet-Loiseau H
    Rev Med Interne; 2007 Oct; 28(10):677-81. PubMed ID: 17559979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.
    Wu KL; Beverloo B; Lokhorst HM; Segeren CM; van der Holt B; Steijaert MM; Westveer PH; Poddighe PJ; Verhoef GE; Sonneveld P; ;
    Br J Haematol; 2007 Feb; 136(4):615-23. PubMed ID: 17223915
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
    Tan D; Teoh G; Lau LC; Lim A; Lim TH; Yap KC; Premalatha P; Lao ZT; Wee N; Choo C; Wee HC; Su S; Lee YS; Lee LH; Hwang W; Goh YT
    Am J Hematol; 2010 Oct; 85(10):752-6. PubMed ID: 20721886
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma.
    Königsberg R; Zojer N; Ackermann J; Krömer E; Kittler H; Fritz E; Kaufmann H; Nösslinger T; Riedl L; Gisslinger H; Jäger U; Simonitsch I; Heinz R; Ludwig H; Huber H; Drach J
    J Clin Oncol; 2000 Feb; 18(4):804-12. PubMed ID: 10673522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
    Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
    Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification.
    Korshunov A; Remke M; Werft W; Benner A; Ryzhova M; Witt H; Sturm D; Wittmann A; Schöttler A; Felsberg J; Reifenberger G; Rutkowski S; Scheurlen W; Kulozik AE; von Deimling A; Lichter P; Pfister SM
    J Clin Oncol; 2010 Jun; 28(18):3054-60. PubMed ID: 20479417
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chromosomal aberrations in 130 patients with multiple myeloma studied by interphase FISH: diagnostic and prognostic relevance.
    Schmidt-Wolf IG; Glasmacher A; Hahn-Ast C; Jüttner A; Schnurr T; Cremer F; Moehler T; Goldschmidt H; Busert B; Schubert R; Schwanitz G
    Cancer Genet Cytogenet; 2006 May; 167(1):20-5. PubMed ID: 16682281
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma.
    An G; Li Z; Tai YT; Acharya C; Li Q; Qin X; Yi S; Xu Y; Feng X; Li C; Zhao J; Shi L; Zang M; Deng S; Sui W; Hao M; Zou D; Zhao Y; Qi J; Cheng T; Ru K; Wang J; Anderson KC; Qiu L
    Clin Cancer Res; 2015 May; 21(9):2148-56. PubMed ID: 25652456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative genomic hybridization of malignant fibrous histiocytoma reveals a novel prognostic marker.
    Larramendy ML; Tarkkanen M; Blomqvist C; Virolainen M; Wiklund T; Asko-Seljavaara S; Elomaa I; Knuutila S
    Am J Pathol; 1997 Oct; 151(4):1153-61. PubMed ID: 9327749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma.
    Sawyer JR
    Cancer Genet; 2011 Jan; 204(1):3-12. PubMed ID: 21356186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data.
    Łastowska M; Viprey V; Santibanez-Koref M; Wappler I; Peters H; Cullinane C; Roberts P; Hall AG; Tweddle DA; Pearson AD; Lewis I; Burchill SA; Jackson MS
    Oncogene; 2007 Nov; 26(53):7432-44. PubMed ID: 17533364
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma.
    Chang H; Ning Y; Qi X; Yeung J; Xu W
    Br J Haematol; 2007 Oct; 139(1):51-4. PubMed ID: 17854306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.
    Chen MH; Qi C; Reece D; Chang H
    Hum Pathol; 2012 Jun; 43(6):858-64. PubMed ID: 22047644
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Array comparative genomic hybridization identifies genetic regions associated with outcome in aggressive diffuse large B-cell lymphomas.
    Robledo C; García JL; Caballero D; Conde E; Arranz R; Flores T; Grande C; Rodríguez J; García E; Sáez AI; González M; Gutiérrez NC; Piris MA; Hernández JM;
    Cancer; 2009 Aug; 115(16):3728-37. PubMed ID: 19517471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.
    Hose D; Rème T; Hielscher T; Moreaux J; Messner T; Seckinger A; Benner A; Shaughnessy JD; Barlogie B; Zhou Y; Hillengass J; Bertsch U; Neben K; Möhler T; Rossi JF; Jauch A; Klein B; Goldschmidt H
    Haematologica; 2011 Jan; 96(1):87-95. PubMed ID: 20884712
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.
    Smetana J; Berankova K; Zaoralova R; Nemec P; Greslikova H; Kupska R; Mikulasova A; Frohlich J; Sevcikova S; Zahradova L; Krejci M; Sandecka V; Almasi M; Kaisarova P; Melicharova H; Adam Z; Penka M; Jarkovsky J; Jurczyszyn A; Hajek R; Kuglik P
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):123-30. PubMed ID: 23291040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of genomic alterations associated with metastasis and cancer specific survival in clear cell renal cell carcinoma.
    Sanjmyatav J; Junker K; Matthes S; Muehr M; Sava D; Sternal M; Wessendorf S; Kreuz M; Gajda M; Wunderlich H; Schwaenen C
    J Urol; 2011 Nov; 186(5):2078-83. PubMed ID: 21944119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma.
    Mendrzyk F; Radlwimmer B; Joos S; Kokocinski F; Benner A; Stange DE; Neben K; Fiegler H; Carter NP; Reifenberger G; Korshunov A; Lichter P
    J Clin Oncol; 2005 Dec; 23(34):8853-62. PubMed ID: 16314645
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic power of abnormal cytogenetics for multiple myeloma: a multicenter study in China.
    Lai YY; Huang XJ; Cai Z; Cao XS; Chen FP; Chen XQ; Chen BA; Fang MY; Feng JF; Fu WL; Guo HY; Hou M; Hou J; Hu Y; Hu XT; Hu XM; Huang LQ; Jin J; Li JY; Li J; Li W; Liang YM; Liu T; Liu QF; Liu YH; Mao P; Ouyang J; Qiu LG; Qiu L; Shao CK; Shi B; Song YP; Sun ZM; Wang QS; Wang C; Wang JM; Wang YS; Wang Z; Wu JB; Wu YX; Xia RX; Xue YQ; Yang BZ; Yang G; Yang ZL; Yu L; Yuan Z; Zhang S; Zhang Y; Zhao HG; Zhao L; Zhou DB; Zou SH; Zhu YF
    Chin Med J (Engl); 2012 Aug; 125(15):2663-70. PubMed ID: 22931972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Prognostic value of 1q21 amplification in multiple myeloma].
    Abramova TV; Obukhova TN; Mendeleeva LP; Pokrovskaya OS; Gribanova EO; Ryzhko VV; Grebenyuk LA; Nareyko MV; Solovyev MV; Votyakova OM; Kulikov SM; Rusinov MA; Savchenko VG
    Ter Arkh; 2017; 89(7):32-38. PubMed ID: 28766538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.